-
Drs. Stuart Connolly and Stefan Hohnloser presented results from the Defibrillator In Acute Myocardial Infarction Trial (DINAMIT). Prior studies had shown that patients with recent myocardial infarction and left ventricular dysfunction are at high risk for death in the period after myocardial infarction.
-
A 12-month program of regular exercise in selected patients with chronic stable angina and significant CAD resulted in a higher event-free survival and exercise capacity at lower costs than PCI.
-
-
The diagnosis of amyotrophic lateral sclerosis (ALS) at an early stage can be difficult. It is desirable to have an accurate diagnostic test due to the prognosis of the illness, as well as the potential ability to treat patients earlier.
-
New alternative anticoagulants now exist that may be equally efficacious as warfarin and allow a more convenient fixed dosing schedule with a superior safety profile.
-
In this randomized, placebo-controlled trial, 667 patients with stable advanced multiple sclerosis were assigned to 1 of 3 groups: oral cannabis, oral tetrahydrocannabinol, or placebo.
-
Thirty-three consecutive patients with l3 or l4 radiculopathy were compared to 19 controls of comparable age to determine the best method for detecting quadriceps weakness in the office setting.
-
The Centers for Medicare & Medicaid Services (CMS; Baltimore) recently asked the Heart Rhythm Society (HRS; Washington) to lead a working group to make recommendation for a national implantable cardioverter defibrillator (ICD) registry. Late in September, CMS posted a draft national coverage determination to expand coverage of ICDs.
-
Adam Berman has been named vice president, research and development for MedicalCV (Minneapolis). He most recently was a regional sales manager for cardiac surgery-focused Coalescent Surgical. Medical CV is focused on developing products for improved patient outcomes by early treatment of cardiovascular disorders.
-
SynCardia Systems (Tucson, Arizona), a developer of cardiac replacement and assist devices, in mid-October received final FDA approval for its CardioWest Temporary Total Artificial Heart (TAH-t) formerly the CardioWest Total Artificial Heart as a bridge to heart transplantation. Specifically, the approval is for use in cardiac transplant-eligible candidates at risk of imminent death from non-reversible biventricular failure.
